SCREENING LICENSES. KOSAN hereby grants to RWJPRI the following fully paid, non-transferable licenses, with the right to grant sublicenses to RWJPRI AFFILIATES, under the KOSAN PATENT RIGHTS and KOSAN KNOW-HOW to conduct screening pursuant to Article 3:
SCREENING LICENSES. 28 12.2.1 Tularik Screening Library................................ 28 12.2.2 Roche Bioscience Screening Library....................... 28 12.3
SCREENING LICENSES. (a) Raven hereby grants to ImmunoGen a non-exclusive, royalty-free, fully paid-up license under the Raven Technology and Raven's interest in any Joint Know-How in the United States solely as necessary to carry out the Research hereunder during the Research Term. Such license shall not be sublicensable.
SCREENING LICENSES. ArQule hereby grants to Monsanto (a) a nonexclusive, worldwide, royalty-free license (without the right to sublicense) to test Mapping Arrays(TM) against Targets in the Field and to perform other analytical work on the compounds in the Mapping Arrays(TM), and (b) an exclusive (including to the exclusion of ArQule), worldwide, royalty-free license (without the right to sublicense) to test any Directed Arrays(TM) for significant functional activity against Targets in the Field and to perform other analytical work on the compounds in the Directed Arrays(TM).
SCREENING LICENSES. ArQule hereby grants to Searxx (x) [*] (b) [*], and (c) [*].
SCREENING LICENSES. ArQule hereby grants to Monsanto (a) a nonexclusive, worldwide, royalty-free license (without the right to sublicense) to test Mapping Arrays™ against Targets in the Field and to perform other analytical work on the compounds in the Mapping Arrays™, and (b) an exclusive (including to the exclusion of ArQule), worldwide, royalty-free license (without the right to sublicense) to test any Directed Arrays™ for significant functional activity against Targets in the Field and to perform other analytical work on the compounds in the Directed Arrays™.
SCREENING LICENSES. ArQule hereby grants to Sugen an exclusive, royalty-free license (without the right to sublicense) to (i) test any Sugen Derivative Compounds for significant functional activity against Targets within the Field and (ii) and to conduct such additional tests on any such Sugen Derivative Compounds within the Field prior to Preclinical Development as Sugen may from time to time determine. Notwithstanding the foregoing, Sugen may from time to time deliver Sugen Derivative Compounds to one or more third parties so as to allow such third parties to perform testing and analytical work on any such Sugen Derivative Compounds; provided, that, prior to delivery of any Sugen Derivative Compounds to any such third party, Sugen and each such third party enter into a materials transfer agreement in a form reasonably acceptable to ArQule.
SCREENING LICENSES. ArQule hereby grants to Wyeth-Ayerst, under ArQule Patent Rights and ArQule Technology (a) a nonexclusive, royalty-free license ***** to test each Mapping Array(TM) for significant functional activity against Targets; and (b) an exclusive, royalty-free license to test each Directed Array(TM) for significant functional activity against Targets. 5.2.
SCREENING LICENSES. SKI hereby grants to LICENSEE an exclusive, worldwide license during the TERM of this AGREEMENT to use the COLLABORATION COMPOUNDS to conduct screening for ANTICANCER ACTIVITY.
SCREENING LICENSES. ArQule hereby grants to Monsanto (a) a nonexclusive, worldwide, royalty-free license (without the right to sublicense) to test ArQule Compounds against Targets in the Field and to perform other analytical work on ArQule Compounds, and (b) an exclusive (including to the exclusion of ArQule), worldwide, royalty-free license (without the right to sublicense) to test any Directed Array Compounds for significant functional activity against Targets in the Field and to perform other analytical work on Directed Array Compounds.
